Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: A phase 1/2 clinical trial

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 688-694

  Zurita, A J ^a   George, D J ^b   Shore, N D ^c   Liu, G ^d   Wilding, G ^d   Hutson, T E ^e   Kozloff, M ^f   Mathew, P ^a   Harmon, C S ^g   Wang, S L ^g   Chen, I ^g   Chow maneval, E ^g   Logothetis, C J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Carolina Urologic Research   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f Ingalls Memorial Hospital   (United States)

^g PFIZER INC   (United States)

Author keywords

Phase 1 2; Prostate cancer; Sunitinib combination

Indexed keywords

DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SUNITINIB;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPONATREMIA; LACRIMATION; LEUKOPENIA; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84863230135     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr349     Document Type: Article

References (34)

1. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008; 14: 1599-1602.
2. Chung LWK, Huang W-C, Sung S-Y et al. Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006; 5: 162-170.
3. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-1966.
4. Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
5. Rao K, Goodin S, Levitt MJ et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005; 62: 115-122.
6. Yu E, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428.
7. Tannock IF, de WR, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
8. Concato J, Jain D, Uchio E et al. Molecular markers and death from prostate cancer. Ann Intern Med 2009; 150: 595-603.
9. Mucci LA, Powolny A, Giovannucci E et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009; 27: 5627-5633.
10. De S, Chen J, Narizhneva NV et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003; 278: 39044-39050.
11. Kitagawa Y, Dai J, Zhang J et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005; 65: 10921-10929.
12. Wu D, Zhau HE, Huang WC et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 2007; 26: 5070-5077.
13. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
14. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormonerefractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001; 61: 2533-2536.
15. Burton JB, Priceman SJ, Sung JL et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008; 68: 7828-7837.
16. Chott A, Sun Z, Morganstern D et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulinlike growth factor receptor. Am J Pathol 1999; 155: 1271-1279.
17. Ko YJ, Small EJ, Kabbinavar F et al. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormonerefractory prostate cancer. Clin Cancer Res 2001; 7: 800-805.
18. Ustach CV, Taube ME, Hurst NJ Jr, et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 2004; 64: 1722-1729.
19. Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003; 95: 458-470.
20. Mathew P, Thall PF, Bucana CD et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007; 13: 5816-5824.
21. Sennino B, Kuhnert F, Tabruyn SP et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009; 69: 4527-4536.
22. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
23. Cumashi A, Tinari N, Rossi C et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270: 229-233.
24. Guerin O, Formento P, Lo NC et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008; 134: 51-57.
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
26. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
27. Armstrong AJ, Tannock IF, De Wit R et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-525.
28. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
29. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebocontrolled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrationresistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28: 18s (Abstr LBA4511).
30. Michaelson MD, Oudard S, Ou Y et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011; 29 (Suppl): (Abstr 4515).
31. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
32. Sonpavde G, Pond GR, Berry WR et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer 2011; 117: doi.10.1002/cncr.25982.
33. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237.
34. Michaelson MD, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920.